A recurrent gain-of-function mutation in ARAF causes lymphatic anomaly in two unrelated patients, and treating one of the patients with an FDA-approved MEK inhibitor resulted in a remarkable recovery, exemplifying the power of precision medicine.
- Dong Li
- Michael E. March
- Hakon Hakonarson